Teradyne, Inc. (TER) Balance Sheet

The balance sheet has strengthened materially, with equity up from $2.6B in 2024Q1 to $3.4B in 2026Q2, a 30.8% increase, while total liabilities rose only modestly. This expansion is largely funded by retained earnings, which grew from $730.3M to $1.4B over the same period, indicating that the AI-driven earnings surge is being converted into book value. The jump in goodwill from $407.6M to $663.8M suggests recent acquisitions, likely in robotics or test solutions, which may carry integration risk but also signal strategic reinvestment.

The company's leverage is negligible, with total debt representing only 2.0% of total assets, and the D/E ratio has improved from 0.12 to 0.03 over the past two quarters. This conservative capital structure appears deliberate, providing a buffer against cyclical downturns and enabling opportunistic investments, as evidenced by the $165.6M acquisition spend in 2026Q2. The low debt also insulates the company from interest rate risk, though the recent spike in debt to $347.1M in 2025Q4 was quickly repaid, suggesting temporary working capital needs rather than a strategic shift.

The asset base is becoming more intangible-heavy, with goodwill now representing 13.5% of total assets, up from 11.9% in 2025Q4, reflecting acquisition activity that may increase impairment risk if growth expectations falter. Meanwhile, net PPE increased 12.4% sequentially to $729.1M, suggesting investment in test capacity to meet AI demand, which aligns with the higher capex noted in cash flow. The current ratio of 2.12 remains healthy, though it has declined from 3.73 in 2024Q1, indicating a more efficient use of working capital as the business scales.

Equity quality is high, with retained earnings accounting for 41.2% of total equity, up from 26.6% in 2025Q4, reflecting strong profitability and a payout ratio that allows for reinvestment. The company continues to repurchase shares, though at a slower pace than in 2025Q3, indicating a balanced approach between returning capital and funding growth. No stock-based compensation was reported, which may understate true equity dilution, but the absence of a dilutive overhang supports the quality of reported equity.

Liquidity is adequate, with a current ratio of 2.12, though it has declined from 3.73 in 2024Q1, indicating a more aggressive use of cash for growth initiatives. Cash balances of $349.5M are lower than historical levels, but the company's ability to generate strong operating cash flow (OCF/NI of 1.25 in 2026Q2) provides a natural buffer. The quick ratio, excluding inventory, would be lower, but given the high turnover of test equipment, inventory is likely liquid, mitigating liquidity risk.

The growth in deferred revenue from $190.7M in 2025Q4 to $256.8M in 2026Q2 suggests that customers are committing capital in advance, which may indicate confidence in future test demand. However, the near-flat sequential change from 2026Q1 to 2026Q2 could imply that the initial AI-driven order surge is stabilizing, warranting monitoring for a potential digestion phase. This aligns with management's conservative guidance for the next quarter, suggesting that while visibility is strong, the pace of growth may moderate.